Introduction
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a major cause of nosocomial infections worldwide and is a serious source of concern due to the fact that multi-drug resistance is critically important to antimicrobials. The resistance to methicillin and other β-lactam antibiotics is conferred by the *mecA* gene, which is inserted into the mobile genetic element staphylococcal chromosomal cassette *mec* (SCC*mec*). Currently, eleven major variants of SCC*mec* (type I to XI) have been characterized (<http://www.sccmec.org/Pages/SCC_TypesEN.html>. Accessed November 26, 2011). Some SCC*mec* elements, including types II and III, harbor additional genes that provide resistance to heavy metals and drugs other than β-lactams, while others, like SCC*mec* types IV and V, usually carry no additional drug resistance genes other than *mecA* ([@B01]). Epidemiological studies based on SCC*mec* typing, sequence types (ST) as defined by multilocus sequence typing (MLST), and pulsed-field gel electrophoresis (PFGE) have identified few pandemic hospital-associated MRSA clones, including the Iberian (USA500-related MRSA; ST247-SCC*mec* I), Brazilian epidemic clone/Hungarian (BEC; ST239-SCC*mec* III), New York/Japan (USA100-related; ST5-SCC*mec* II), Paediatric (USA800-related; ST5-SCC*mec* IV or VI), EMRSA-15 (Barnim epidemic MRSA; ST22-SCC*mec* IV), EMRSA-16 (USA200-related; ST36-SCC*mec* II), and Berlin (USA600-related; ST45-SCC*mec* II/IV) ([@B01]). MLST analysis, based on sequence variation at seven housekeeping genes, has shown that these pandemic MRSA clones evolved from six different clonal complexes (CC1, CC5, CC8, CC22, CC30, and CC45), each arising from a distinct ancestral genotype ([@B02],[@B03]). There is clear evidence that successful methicillin-susceptible *S. aureus* (MSSA) clones have become MRSA by the introduction of SCC*mec* on more than one occasion. These horizontal transfers of the *mec* element into different lineages have been highly significant in MRSA evolution ([@B02]). However, despite the fact that many SCC*mec* types, including I, II, and IV, have entered in more than one MSSA background, the SCC*mec* type III is uniquely associated with the ST239 subgroup of CC8 ([@B04]). In fact, ST239 has a mosaic chromosome that seems to have originated from an ST8 ancestral that received a significant part of its genome from an ST30 background ([@B02]).

Although each geographical location would only have a limited number of MRSA clones in its hospitals, the geographical distribution of MRSA clones continuously evolves by the introduction of new clones or the evolution of an existing one, usually better adapted and showing enhanced pathogenic properties ([@B05]). As a result, the 21st century has been marked by important changes in the epidemiology of MRSA with the emergence of community-associated, non-multidrug-resistant clones as important hospital pathogens, including USA300, and multidrug-resistant clones, traditionally linked to the hospital, as etiological agents of community infections ([@B06],[@B07]). Because specific MRSA clones can display different antibiotic resistance profiles, monitoring the distribution and evolution of MRSA is important in controlling bacterial transmission and supporting the use of effective treatments against the most prevalent clones in each local region. In Brazil, despite the high prevalence of MRSA, published data on susceptibility and molecular evolution of MRSA over time are still scarce. Therefore, the aim of this study was to compare the molecular characteristics and the antimicrobial susceptibility profiles of clinical MRSA isolates obtained at two distinct times, within a 10-year interval, in a Brazilian hospital.

Material and Methods
====================

Study design and identification of isolates
-------------------------------------------

The study was performed over two time periods with a 10-year interval (1998 and 2008) in the hospital of Universidade Federal do Triângulo Mineiro (UFTM). This hospital, located in Minas Gerais State in Southeastern Brazil, is a 294-bed tertiary-care teaching hospital with a 40-bed intensive care unit (ICU) and a full range of medical specialties. The *S. aureus* isolates recovered from hospitalized patients were identified by conventional routine methods (Gram staining, catalase and free coagulase tests). Only the first isolate of each patient was considered. All isolates were confirmed as MRSA by PCR amplification of an internal fragment of the *mecA* gene ([@B08]). The present study was approved by the Ethics Committee of Universidade Federal do Triângulo Mineiro.

Susceptibility testing
----------------------

The susceptibility profile was determined by the disk diffusion method for the following antimicrobial agents: cefoxitin (CFX), chloramphenicol (CLO), ciprofloxacin (CIP), clindamycin (CLI), erythromycin (ERY), gentamicin (GEN), linezolid (LIN), norfloxacin (NOR), rifampicin (RIF), tetracycline (TET), and trimethoprim-sulfamethoxazole (SXT) (DME, Brazil). The minimal inhibitory concentration (MIC) was determined by the broth dilution method for oxacillin (OXA) and vancomycin (VAN) (Sigma, USA). The disk diffusion test and MIC were performed and interpreted according to guidelines established by the Clinical and Laboratory Standards Institute ([@B09]). Inducible macrolide, lincosamide, and streptogramin B resistance (MLS~Bi~) was tested using the D-test ([@B09]). *S. aureus* ATCC 25923 and *S. aureus* ATCC 29213 were used for quality control purposes.

Molecular characterization
--------------------------

SCC*mec* typing was performed for all MRSA isolates using a PCR multiplex method ([@B10]). The CC was resolved using the restriction-modification (RM) tests according to Cockfield et al. ([@B03]). PFGE of the *Sma*I-digested DNA was performed as described previously ([@B11]). PFGE-banding patterns were analyzed by visual inspection and interpreted according to the criteria of Tenover et al. ([@B12]). Isolates were considered to belong to different types when the banding patterns revealed more than six-band differences. Representative MRSA isolates of BEC (BMB9393) ([@B11]) and of USA100, USA300, USA500, and USA800 (kindly provided by Paul Dunman, University of Nebraska Medical Center, USA) were used in the molecular experiments as reference strains. MLST was carried out only for selected isolates previously typed by PFGE and SCC*mec* that were not related to the reference strains used. The allelic profiles and ST were assigned with reference to the MLST database (<http://www.mlst.net>). The *lukF* gene, coding for the F-subunit of the Panton-Valentine leukocidin (PVL) was assayed by PCR using primers and procedures described by Ribeiro et al. ([@B13]). The DNA from the USA300 prototype was used as positive control for the *lukF* gene.

Statistical analysis
--------------------

Data were analyzed with the Epi-Info statistical software (version 3.5.1; CDC, USA). The chi-square or the Fisher exact test was used to compare the antimicrobial susceptibility rates between the two study periods. Differences were regarded as significant when P ≤ 0.05.

Results
=======

A total of 208 and 151 non-repetitive clinical *S. aureus* isolates were recovered in 1998 and 2008, respectively, including cases of hospital infections, colonizations and outside-hospital acquisitions. Among them, 48 (23%) in 1998 and 56 (37%) in 2008 were classified as MRSA according to the results of *mec*A detection and the phenotypic susceptibility tests performed ([Table 1](#t01){ref-type="table"}). The MRSA isolates were obtained from the following sites: blood and catheter tips: 21 (1998) and 20 (2008); skin or surgical site: 19 (1998) and 25 (2008); lower respiratory tract secretions: 5 (1998) and 9 (2008); urine: 2 (1998) and 2 (2008); upper respiratory tract secretion: 1 (1998). All the 48 MRSA isolated in 1998 harbored SCC*mec* III. However, among the 56 isolates recovered in 2008, 48 (85.7%) harbored SCC*mec* III and 8 (14.3%) carried diverse types of SCC*mec*, including SCC*mec* I (N = 5; 8.9%), SCC*mec* IV (N = 2; 3.6%) and SCC*mec* II (N = 1; 1.8%). The SCC*mec* IV isolates were tested for the presence of the PVL gene (*lukF*) but amplification products were not detected.

Table 1.Antimicrobial susceptibility of the methicillin-resistant *Staphylococcus aureus* (MRSA) isolates recovered in 1998 and 2008 from a Brazilian tertiary hospital.Antimicrobial agentNumber of susceptible isolates (%)1998 (N = 48)2008 (N = 56)Chloramphenicol2 (4.2)39 (69.6)^a^[\*](#TFN04t01){ref-type="table-fn"}Ciprofloxacin0 (0)1 (1.8)Clindamycin0 (0)2 (3.6)Erythromycin0 (0)0 (0)Gentamicin0 (0)4 (7.1)Linezolid48 (100)56 (100)Norfloxacin0 (0)2 (3.6)Rifampicin7 (14.6)24 (42.9)^b^[\*](#TFN04t01){ref-type="table-fn"}Tetracycline3 (6.3)6 (10.7)Trimethoprim-sulfamethoxazole0 (0)8 (14.3)^c^[\*](#TFN04t01){ref-type="table-fn"}Vancomycin48 (100)56 (100)[^2][^3][^4][^5]

The antimicrobial susceptibility profiles of the MRSA isolates are summarized in [Table 1](#t01){ref-type="table"}. During both periods (1998 and 2008), MRSA isolates were highly resistant to ERY, CIP, CLI, NOR, GEN, and TET. However, MRSA isolates recovered in 2008 showed a significant increase in susceptibility to CLO (69.6 *vs* 4.2%; P \< 0.001), RIF (42.9 *vs* 14.6%; P = 0.002) and SXT (14.3 *vs* 0%; P = 0.006) compared to those recovered in 1998. A large proportion of MRSA isolates susceptible to CLO (79.5%; 31/39) and RIF (70.8%; 17/24) harbored SCC*mec* III, while none of the isolates susceptible to SXT carried this SCC*mec* type. Seven (14.6%) isolates in 1998 and none in 2008 showed inducible resistance to CLI (MLS~Bi~). No MRSA isolate was resistant to VAN and LIN.

Based on the knowledge that SCC*mec* III has entered only the ST239 background and that BEC isolates predominate in Brazil, only 13 SCC*mec* III representative MRSA isolates from 1998 (4 isolates) and 2008 (9 isolates) were analyzed by PFGE and RM tests. Because in 2008 susceptibility to CLO and RIF emerged among the SCC*mec* III isolates, a higher number of SCC*mec* III isolates were selected in 2008 in order to include representatives of these susceptibility profiles. Indeed, because SCC*mec* I, II and IV can be frequently found in different MRSA backgrounds, all 8 non-SCC*mec* III isolates detected in this study were analyzed by PFGE and RM tests. These 21 MRSA isolates analyzed showed 5 different PFGE types, namely A to E ([Figure 1A and B](#f01){ref-type="fig"}). All but one of the 13 SCC*mec* III isolates analyzed displayed PFGE pattern A ([Figure 1A](#f01){ref-type="fig"}, subtypes A~1-6~) similar to BMB9393, a prototype strain of BEC. The 13 SCC*mec* III isolates were confirmed to belong to CC8 by RM tests. One isolate that also displayed SCC*mec* III and CC8, recovered in 2008, had more than six different bands from BEC and other prototype strains ([Figure 1B](#f01){ref-type="fig"}, type E, lane 10).

Figure 1.Pulsed-field gel electrophoresis (PFGE) patterns of *Sma*I-digested genomic DNA of MRSA isolates recovered in 1998 and 2008 from a Brazilian tertiary hospital. *A*, MRSA isolates displaying patterns quite similar to that of BEC (BMB9393). *Lane 1*, DNA molecular size marker (λ-ladder, 50-1000 kb); *lane 2*, strain BMB9393, representative of the BEC; *lanes 3-5*, pattern A~1~ (isolates 1, 2, and 15; 1998); *lane 6*, pattern A~2~ (isolate 19; 1998); *lanes 7* and *8*, pattern A~1~ (isolates 12 and 15; 2008), *lane 9*, pattern A~3~ (isolate 2; 2008); *lane 10*, pattern A~4~ (isolate 42; 2008); *lane 11*, pattern A~2~ (isolate 53; 2008); *lanes 12* and *13*, pattern A~5~ (isolates 8 and 40; 2008); lane 14, pattern A~6~ (isolate 50; 2008). *B*, MRSA isolates displaying patterns different from those of BEC. *Lane 1*, DNA molecular size marker (λ-ladder, 50-1000 kb); *lane 2*, pattern B (isolate 214; 2008); *lanes 3-5*, pattern C~1~ (isolates 3, 119, 251; 2008); *lanes 6* and *7*, pattern C~2~ (134 and 140; 2008); *lanes 8* and *9*, pattern D~1~ and D~2~ (isolates 174 and 190; 2008); *lane 10*, pattern E (isolate 9; 2008). BEC = Brazilian epidemic clone of MRSA; MRSA = methicillin-resistant *Staphylococcus aureus*.

Among the remaining isolates recovered in 2008, one MRSA (isolate 214) displaying SCC*mec* IV differed from BEC pattern A~1~ by more than six bands and belonged to CC8. This PFGE pattern, named type B ([Figure 1B](#f01){ref-type="fig"}, lane 2), was quite similar to the representative of the USA300 clone. All the 5 (8.9%; 5/56) MRSA isolates carrying SCC*mec* I were grouped in the PFGE cluster C ([Figure 1B](#f01){ref-type="fig"}, subtype C~1~, lanes 3, 4, and 5; subtype C~2~, lanes 6 and 7) and belonged to CC5 but differed from the reference strains by more than six PFGE bands. Because this clone was novel in this country, one CC5-SCC*mec* I MRSA (isolate 119) was selected for MLST analysis and displayed the allelic profile 1-4-1-4-12-1-10, which defines ST5. Two isolates grouped in the PFGE type D also belonged to CC5. Of these, one (isolate 214) harbored SCC*mec* IV and had a PFGE pattern ([Figure 1B](#f01){ref-type="fig"}, subtype D~1~, lane 8) similar to that of the USA800/Paediatric clone (ST5-SCC*mec* IV). The other isolate of cluster D ([Figure 1B](#f01){ref-type="fig"}, subtype D~2~, lane 9) displayed SCC*mec* II and was considered to be related to the USA100/New York/Japan clone (ST5-SCC*mec* II).

The antimicrobial susceptibility profiles and oxacillin MIC of the 21 MRSA isolates analyzed by SCC*mec* typing, PFGE and RM tests are listed in [Table 2](#t02){ref-type="table"}. All isolates belonging to CC5 displayed SCC*mec* I, II or IV and were susceptible to SXT, while only one CC8 isolate, harboring SCC*mec* IV (USA300-related), showed susceptibility to this drug.

Table 2.Molecular characteristics, minimal inhibitory concentration (MIC) for oxacillin and antimicrobial susceptibility profile of 21 representative MRSA isolates recovered in 1998 and 2008 from a Brazilian tertiary hospital.Year of isolationIsolatePulsotypeSCC*mec* typeCCOXA MICAntimicrobial susceptibilityPFGE clone19981A1IIICC8256LIN, VANBEC2A1IIICC8256LIN, VANBEC15A1IIICC8\>256LIN, VANBEC19A2IIICC8256LIN, VANBEC200812A1IIICC8256LIN, RIF, VANBEC15A1IIICC8\>256CLO, LIN, RIF, VANBEC2A3IIICC8256CLO, LIN, RIF, VANBEC42A4IIICC8256LIN, VANBEC53A2IIICC8\>256LIN, VANBEC8A5IIICC8256CLO, LIN, RIF, TET, VANBEC40A5IIICC8128LIN, RIF, VANBEC50A6IIICC8\>256LIN, VANBEC214BIVCC816CLO, CLI, GEN, LIN, RIF, SXT, TET, VANUSA3003C1ICC5256CLO, LIN, RIF, SXT, VANEMRSA-3/Cordobes119C1ICC5256CLO, LIN, RIF, SXT, VANEMRSA-3/Cordobes251C1ICC5256CLO, LIN, NOR, RIF, SXT, TET, VANEMRSA-3/Cordobes134C2ICC5\>256CLO, LIN, RIF, SXT, VANEMRSA-3/Cordobes140C2ICC5\>256CLO, LIN, SXT, VANEMRSA-3/Cordobes174D1IVCC516CLO, CLI, GEN, LIN, NOR, RIF, SXT, TET, VANPC (USA800)190D2IICC532CLO, GEN, LIN, RIF, SXT, TET, VANNY/J (USA100)9EIIICC8256CLO, LIN, RIF, VANUndetermined[^6]

Discussion
==========

The use of a variety of molecular typing techniques allowed the detection of MRSA clones circulating in our hospital at different time periods. In this study, in 1998, multidrug-resistant isolates harboring SCC*mec* III were the only MRSA detected in the hospital, whereas in the latter study period (2008) new epidemic MRSA clones emerged, accounting for 14.3% of the MRSA isolates recovered during this period. It is noteworthy that all non-SCC*mec* III isolates found in 2008 were characteristically susceptible to SXT and all but one belonged to CC5.

Actually, SCC*mec* III is uniquely associated with the widespread ST239-related MRSA ([@B04]) and ST239-III MRSA is an universally occurring multidrug-resistant lineage, first described in 1992 in Brazil ([@B11]), responsible for an incredible number of hospital-acquired infections in several countries on diverse continents ([@B01]). However, ST239 isolates have been replaced by other MRSA backgrounds in some countries. In Portugal, from 1996 to 2000, BEC isolates were the most common ST239 MRSA inside hospitals, whereas, since 2001, this clone has drastically declined in that country with a concomitant increase of isolates belonging to EMRSA-15 (ST22-SCC*mec* IV) ([@B14]). In Argentina, Chile and Paraguay, the BEC was displaced by the Cordobes clone (ST5-SCC*mec* I) ([@B15]). More recently, a study conducted in Rio de Janeiro, Brazil, showed that isolates classified as ST1-SCC*mec* IV (USA400-related) were replacing BEC in the two hospitals evaluated ([@B16]).

Besides the SCC*mec* III isolates, the only CC8 MRSA found in our study was related to USA300 (ST8-SCC*mec* IV), which has been mostly associated with community acquired (CA)-MRSA infections ([@B01],[@B06]). Usually, USA300-related isolates have been linked to the production of PVL and susceptibility to almost all classes of non-β-lactamic antimicrobials ([@B01]). Despite the fact that the PVL-encoding gene *lukF* was not detected in the USA300-related isolate found in our hospital, this isolate was recovered from a patient with orbital cellulitis classified as a CA infection, according to CDC guidelines. In Brazil, infections associated with PVL-negative USA300 isolates have already been reported ([@B13],[@B17],[@B18]).

All other non-SCC*mec* III isolates recovered in 2008 were allocated to CC5. In contrast to ST239, MRSA isolates belonging to ST5 (CC5) have been associated with different SCC*mec* types (i.e., I, II, and IV) comprising a large number of MRSA clones, both hospital acquired (HA)- and CA-MRSA, some of which have attained pandemic spread ([@B02]). Most of the CC5 isolates found in the current study harbored SCC*mec* I and clustered in the same PFGE type. MLST analysis of one of these isolates showed that it belonged to ST5. Four isolates were associated with cases of colonization and one (isolate 3) with a case of HA pneumonia in an ICU patient.

The genotype ST5-SCC*mec* I is shared by the EMRSA-3 and Cordobes clones. The EMRSA-3 clone, detected in the United Kingdom in 1987-1988, is among the most common MRSA in that region along with EMRSA-15 and EMRSA-16 ([@B02]). Studies conducted in Chile (1997 and 1998) and Argentina (1999) have identified the Cordobes clone, which is genetically related to the EMRSA-3 but presents differences in the PFGE pattern and *spa* type ([@B15],[@B19],[@B20]). It is of note that in hospitals of these countries as well as in Paraguay, the ST239 isolate was replaced by the multidrug-resistant Cordobes clone ([@B15]). To our knowledge, isolates related to the EMRSA-3 and Cordobes clones have not been reported in southeast Brazil thus far. After our study was concluded, this clone was reported in Porto Alegre, Rio Grande do Sul State ([@B21]), which is the southernmost state in Brazil located on the border with Argentina.

Two other CC5 MRSA clones, related to the USA800/Paediatric clone (SCC*mec* IV) and USA100/New York/Japan (SCC*mec* II), were sporadically detected in our hospital. MRSA isolates belonging to both of these international clones, which are commonly spread in nosocomial settings, had been previously described in Brazil ([@B16],[@B22],[@B23]). In other Latin America countries, the USA800/Paediatric and USA100/New York/Japan CC5 clones have successfully spread along with the Cordobes clone ([@B15]).

During both periods of the study (1998 and 2008), MRSA isolates were highly resistant to ERY, CIP, CLI, NOR, GEN, and TET although all of them were susceptible to VAN and LIN. During the last study period (2008), we detected a great proportion of SCC*mec* III isolates susceptible to CLO and RIF compared to those observed 10 years earlier. Although we did not test this hypothesis, these increased susceptibilities may possibly be an indication of the entry of a novel ST239-SCC*mec* III variant in our hospital. In a Chinese hospital, for instance, it was demonstrated that the ST239-*spa* t037 clone, displaying increased susceptibility to RIF, was replaced by the ST239-*spa* t030 clone, frequently more resistant to this drug ([@B24]). After 2000, the prevalence of MRSA rapidly increased in that hospital, which was coincident with the emergence of the ST239-*spa* t030 clone that, according to the authors, seemed to have a stronger survival advantage and could easily be transmitted. In that study, ST239 was also the most common lineage over time ([@B24]). In fact, in previous studies, we had found that some ST239-SCC*mec* III variants might display an increased ability to accumulate biofilm and to invade and adhere to human airway epithelial cells ([@B05]).

The increased susceptibility to SXT detected in 2008 was due to the emergence of CC5 (SCC*mec* I, II and IV) isolates since all of them were susceptible to this drug. In contrast, SCC*mec* III isolates were typically resistant to SXT, as shown in our study and others ([@B14],[@B16]). Therefore, the analysis of the antimicrobial susceptibility profile may be useful as a phenotypic marker for a preliminary search for new MRSA clones in hospitals where ST239-SCC*mec* III-related isolates predominate. Moreover, SXT might offer an additional therapeutic option to clinicians for the treatment of infections caused by the more susceptible MRSA isolates because it is inexpensive, bactericidal, has an acceptable toxicity profile, penetrates well into tissue and is available for administration by both the oral and intravenous routes. However, controlled clinical trials describing successful therapy with SXT for MRSA infections compared to VAN and other available anti-MRSA drugs are still very scarce ([@B25]).

Despite the predominance of SCC*mec* III MRSA isolates in our hospital, changes in the clonal nature were detected in 2008 represented by the entry of diverse MRSA lineages, almost all belonging to CC5. In addition, our data suggest that SXT susceptibility may be used as an antimicrobial marker to indicate the potential emergence of new MRSA clones, mainly in hospitals where ST239 isolates predominate. The emergence of MRSA isolates genetically related to the EMRSA-3/Cordobes clone in southeast Brazil indicates that the spread of the Cordobes clone in our country is not limited to the Argentinean borders. Finally, these data show that local studies on the molecular epidemiology of MRSA are essential to trace the entry of new clones and to collect information on antimicrobial susceptibility to guide decisions regarding the choice of appropriate empirical therapy for invasive MRSA infections.
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[^1]: Both are senior authors and have contributed equally.

[^2]: Thirty-one (79.5%) of the 39 and

[^3]: 17 (70.8%) of the 24 MRSA isolates susceptible to chloramphenicol and rifampicin, respectively, carried SCC*mec* III.

[^4]: None of the 8 MRSA isolates susceptible to trimethoprim-sulfamethoxazole carried SCC*mec* III. SCC*mec* III = staphylococcal chromosomal cassette *mec* III; MRSA = methicillin-resistant *Staphylococcus aureus*.

[^5]: P \< 0.05 compared to 1998 (chi-square or Fisher exact test).

[^6]: MRSA = methicillin-resistant *Staphylococcus aureus;* SCC*mec* = staphylococcal chromosomal cassette *mec*; CC = clonal complex; PFGE = pulsed-field gel electrophoresis; CIP = ciprofloxacin; CLI = clindamycin; CLO = chloramphenicol; GEN = gentamicin; LIN = linezolid; OXA = oxacillin; RIF = rifampicin; SXT = trimethoprim-sulfamethoxazole; TET = tetracycline; VAN = vancomycin; BEC = Brazilian epidemic clone; PC = pediatric clone; NY/J = New York/Japan clone.
